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Increasing evidence suggests that the c-Abl protein tyrosine kinase could play a role in the pathogenesis of
Parkinson’s disease (PD) and other neurodegenerative disorders. c-Abl has been shown to regulate the degrad-
ation of two proteins implicated in the pathogenesis of PD, parkin anda-synuclein (a-syn). The inhibition of par-
kin’s neuroprotective functions is regulated by c-Abl-mediated phosphorylation of parkin. However, the
molecular mechanisms by which c-Abl activity regulates a-syn toxicity and clearance remain unknown.
Herein, using NMR spectroscopy, mass spectrometry, in vitro enzymatic assays and cell-based studies, we
established thata-syn is abonafidesubstrate for c-Abl. In vitrostudies demonstrate that c-Abl directly interacts
with a-syn and catalyzes its phosphorylation mainly at tyrosine 39 (pY39) and to a lesser extent at tyrosine 125
(pY125). Analysis of human brain tissues showed that pY39a-syn is detected in the brains of healthy individuals
and those with PD. However, only c-Abl protein levels were found to be upregulated in PD brains. Interestingly,
nilotinib, a specific inhibitor of c-Abl kinase activity, induces a-syn protein degradation via the autophagy and
proteasome pathways, whereas the overexpression of a-syn in the rat midbrains enhances c-Abl expression.
Together, these data suggest that changes in c-Abl expression, activation and/or c-Abl-mediated phosphoryl-
ation of Y39 play a role in regulating a-syn clearance and contribute to the pathogenesis of PD.
INTRODUCTION
The tyrosine kinase c-Abl is involved in regulating several
cellular processes and has been implicated in the development
of the central nervous system (1) by controling neurogenesis,
neurite outgrowth and neuronal plasticity (2–7). More recently,
increasing evidence from various experimental model systems
has also revealed that c-Abl is activated in neurodegenerative
diseases (8) such as Alzheimer’s disease (AD) (9–11), Parkin-
son’s disease (PD) (12,13), Niemann–Pick type C disease (14)
and tauopathies (15). However, the mechanisms by which
c-Abl contributes to the initiation and/or propagation of the
pathogenic events underlying these neurodegenerative diseases
remain poorly understood.
c-Abl is a 120 kDa protein belonging to the cytoplasmic tyro-
sine kinase family. Similar to Src kinases, c-Abl possesses
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sequential SH3 and SH2 domains followed by a core catalytic
domain with tyrosine kinase activity (16,17). Moreover, c-Abl
has been detected in the nucleus and has a unique myristoylated
N-terminal region that negatively regulates its kinase activity
(16). The C-terminal region of c-Abl contains nuclear localiza-
tion sequences and an F-actin-binding domain (16). c-Abl is a
tightly regulated kinase and is activated through oxidative
(18,19) or genotoxic stress (20), and the function of this
protein is dependent on its subcellular localization (21–23).
Cytoplasmic c-Abl regulates cellular adhesion and survival
pathways, whereas c-Abl in the nucleus or in the mitochondria
induces cell cycle arrest and apoptosis upon genotoxic stress
(21,22,24).
Changes in c-Abl levels or activation have been linked to the
pathogenesis of AD. For example, the level of activated c-Abl
(c-Abl phosphorylated at Y412, which is a marker of high
kinase activity) is higher than normal in the hippocampus of
AD patients (25) and c-Abl colocalizes with AD pathology in
both AD human brains and transgenic (tg) animal models
(8,11). In addition, c-Abl activation has been directly asso-
ciated with the molecular mechanisms that govern amyloid
beta-induced toxicity in primary hippocampal cultures (25).
Together, these studies indicate that c-Abl acts at different
stages in the amyloid cascade and influences both amyloid
toxicity and AD pathology, including the formation of granu-
lovacuolar degeneration bodies and hyperphosphorylated
tau (8,11,15).
Several lines of evidence have suggested that aberrant activa-
tion of c-Abl plays important roles in the pathogenesis of PD
(12,13,26): (i) the c-Abl protein level is upregulated in post-
mortem striatum of PD patients (26) and the phosphorylation
of c-Abl at Y412 is also enhanced in the substantia nigra
(12,26) and striatum (12) of PD patients; (ii) two independent
studies have shown that c-Abl phosphorylates parkin and
impairs its E3 ligase activity, leading to loss of dopaminergic
neurons in the substantia nigra (12,13); (iii) the inhibition of
c-Abl activity by imatinib/Gleevec (27), nilotinib/Tasigna (28)
or bafetinib/INNO-406 (29) protects against the loss of dopa-
minergic neurons in the substantia nigra of WT mice (12,26).
More recently, Hebron et al. showed that c-Abl regulates the
clearance ofa-syn (26), a synaptic protein that has been strongly
implicated in the pathogenesis of PD by evidence from genetic,
pathological and animal modeling studies (30).
a-Syn is a 14 kDa protein that is found in the intraneuronal in-
soluble fibrillar aggregates called Lewy bodies (LBs) and Lewy
neurites within the brains of patients diagnosed with PD (31,32)
and other neurodegenerative a-synucleinopathies, including de-
mentia with Lewy bodies (DLB) (33). The pathogenic relevance
of a-syn aggregation and the mechanism by which these LBs
are formed remain subjects of intense investigation and debate.
However, the identification of missense mutations in the SNCA
gene in some familial forms of PD and evidence that increased ex-
pression due to gene duplication or triplication is sufficient to
cause familial forms of PD have reinforced the central role of
this protein in the etiology of both sporadic and familial cases of
PD (34–42). Recently, Hebron et al. provided evidence for a bi-
directional relationship between a-syn and c-Abl in vivo,
whereby an increase ina-syn expression induces the phosphoryl-
ation and subsequent activation of c-Abl, and conversely, an in-
crease in the c-Abl expression and activity results in a-syn
accumulation (26,43), suggesting that inhibition of c-Abl might
constitute a viable strategy for attenuating a-syn accumulation
and protecting against a-syn toxicity in PD. This hypothesis is
supported by the observation that nilotinib increases a-syn clear-
ance via the autophagy pathway and protects against
a-syn-induced loss of dopaminergic neurons in a mouse model
of PD (13,26). Nevertheless, the molecular mechanisms by
which changes in c-Abl expression levels and/or activation regu-
late a-syn clearance and toxicity in vivo remain unknown.
Given our interest in the role of post-translational modifications
in regulating a-syn functions in health and disease and previous
observations demonstrating c-Abl-mediated neuroprotection in
PD models, we sought to further explore the relationship
between a-syn and c-Abl. Towards this goal, we sought to (i) de-
termine whether a-syn is a physiological substrate of c-Abl, (ii)
identify the tyrosine residues that are phosphorylated by c-Abl
in vitro and validate our findings in vivo and (iii) determine the
role of c-Abl-mediated phosphorylation in regulating a-syn
clearance.
In this study, we demonstrate, for the first time, that a-syn is a
bona fide substrate of c-Abl and showed that c-Abl phosphorylates
a-syn, primarily at tyrosine 39 (Y39) and to a lesser extent at tyro-
sine 125 (Y125) in vitro, in neuroblastoma cell lines and in primary
cultures ofmousecorticalneurons.We alsoprovidedirect evidence
that a-syn phosphorylated at Y39 is present in normal and PD
human brain tissues. The phosphorylation of a-syn at Y39 can be
abolished by using specific c-Abl inhibitors (imatinib, nilotinib
and GNF-2) (44) or through the downregulation of c-Abl protein
levels using siRNA. Conversely, the activation of c-Abl using
DPH (5-[3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl]-2,4-imi-
dazolidinedione) (45) enhances a-syn phosphorylation at Y39.
Moreover, the effects of c-Abl-mediated phosphorylation on
a-syn clearance were also investigated.
RESULTS
c-Abl preferentially phosphorylates a-syn at Y39
in an in vitro kinase assay
a-syn contains four tyrosine residues (Y39, Y125, Y133 and
Y136). Y125, Y133 and Y136 have previously been shown to
undergo phosphorylation by several tyrosine kinases including
c-Src (46), Fyn (47) and the Syk family (48). However, no
kinase has been shown to phosphorylate a-syn at Y39. We first
investigated whether c-Abl could be a tyrosine kinase for a-syn,
using in vitro kinase assays. Purified a-syn was incubated in the
presence or absence of a recombinant active c-Abl fragment com-
prising the SH2 and catalytic domains (residues 138–534), also
known as SH2-CD c-Abl. In the presence of c-Abl, electrospray
ionization mass spectrometry (ESI-MS) analysis showed the ap-
pearance of a new peak with a deconvoluted mass of 14 541 Da
for WT a-syn, which is consistent with a single phosphorylation
event (calculated mass: 14 540 Da) (Fig. 1A). Mutating Y39 to
phenylalanine (Y39F) nearly abolished a-syn phosphorylation
by c-Abl suggesting that Y39 is the primary and preferred site
for c-Abl-mediated a-syn phosphorylation (Fig. 1A). In contrast,
the Y125F mutant was efficiently phosphorylated at Y39 even to a
higher extent than WT a-syn (Fig. 1A), suggesting that the phos-
phorylation at Y125 could decrease the propensity of c-Abl to
phosphorylate a-syn at Y39. No phosphorylation was detected
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Figure1. c-Abl preferentially phosphorylatesa-syn at Y39 residue in vitro. (A) Mass spectrometry analysis of analytical in vitrophosphorylation assays of WT, Y39F,
Y125F or the double mutant Y39F/Y125F a-syn with (+c-Abl) or without (2c-Abl) recombinant SH2-CD c-Abl. Phosphorylation was detected by a +80 Da mass
shift. ‘N’ denotes nonphosphorylated starting material peaks, ‘P’ indicates the peaks corresponding to phosphorylated proteins. (B) WB analysis of the same reactions
shown in (A) was performed using different phospho-specific a-syn antibodies in order to confirm that phosphorylation occurred at the expected sites. (C) Recom-
binant SH2-CD c-Abl kinase was used to perform kinase assays with increasing concentrations of a-syn peptides (dotted black line: biotin-a-syn (34–44)-NH2; full
gray line: biotin-a-syn (119–129)-NH2) or the positive control CrkL peptide (full black line). Specific activity was calculated and plotted over the substrate concen-
tration (Michaelis–Menten graph). The graph shows the mean+SD of a representative experiment performed in triplicates. (D) Quantification of FL WTa-syn (dark
gray bars) and Y39F (light gray bars) phosphorylation by recombinant WT SH2-CD c-Abl performed at different substrate concentrations (top panel). Bars represent
the mean+SD of a representative experiment performed in triplicates. Representative autoradiography (bottom panel) obtained from a SDS–PAGE gel from which
the Coomassie-stained bands were cut and measured by scintillation counting to obtain the data in the top panel. (E) 1H/15N HSQC NMR spectrum of WTa-syn in the
presence of c-Abl at t ¼ 0 (black peaks) and after t ¼ 5–6 h of phosphorylation (red peaks). The two-framed peaks in the upper right portion of the spectrum corres-
pond to Gly41 in the unphosphorylated protein (black peak labeled ‘#’) and in the Y39-phosphorylated form (red peak labeled ‘∗’). (F) Kinetics of a-syn phosphor-
ylation at Y39 measured by NMR. The phosphorylation-dependent chemical shift changes of Gly41 (see panel C) and Leu 39 (see Supplementary Material, Fig. S1B)
were used to quantify phosphorylation at Y39 as the intensity of the peak arising from the phosphorylated protein relative to the sum of the intensities of the peaks
arising from both phosphorylated and unphosphorylated protein. Values ,0 (due to noise-related negative peak intensities) were set to 0.
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for the Y39F/Y125F double mutant (Fig. 1A, bottom panel), sug-
gesting that c-Abl does not significantly phosphorylate a-syn at
Y133 or Y136. These results show that Y39 is the primary
residue phosphorylated by c-Abl in vitro.
To characterize a-syn phosphorylation at Y39 in cells and
brain tissues, we generated an anti-pY39 a-syn antibody
against a synthetic peptide (amino acids 34–45) harboring the
phosphate group at Y39. No previous reports described the
availability or use of anti-pY39 antibodies. The specificity of
this antibody for pY39 a-syn was validated using a peptide-
based dot blot assay (Supplementary Material, Fig. S1A and
B) and confirmed by western blot (WB) analysis of mammalian
cell lines (Supplementary Material, Fig. S1C). We further
investigated the specificity of the pY39 antibody using immuno-
histochemistry (IHC) (Supplementary Material, Fig. S1E and F)
or immunocytochemistry (ICC) (Supplementary Material,
Fig. S1G) in hippocampal primary neurons. For IHC, we used
brains from PDGF-a-syn tg mice (49), displaying abundant
a-syn accumulation in the neocortex and limbic system (a-syn
tg), or a-syn KO mice (a-syn KO). As shown in Fig. S1E, the
pY39 signal was detectable only in tg mice overexpressing
a-syn and was totally absent in brains in which a-syn is not
expressed (KO mice). Similar results were obtained in primary
hippocampal neurons from WT or a-syn KO mice (Supplemen-
tary Material, Fig. S1G). Moreover, when the pY39 antibody
was preincubated with a specific blocking peptide, no positive
signal was detected by WB (Supplementary Material,
Fig. S1D) or by IHC (Supplementary Material, Fig. S1F) in tg
mouse tissues. Taken together, these results establish the speci-
ficity of the anti-pY39 antibody used in this study.
WB analysis of samples of recombinant a-syn in vitro phos-
phorylated by active SH2-CD c-Abl confirmeda-syn phosphoryl-
ation at Y39 and Y125 residues (Fig. 1B), consistent with the
results obtained by mass spectrometry (MS) (Fig. 1A). Neverthe-
less, neither intact-protein MS nor WBs using phospho-specific
antibodies allowed quantitative comparison of the relative affin-
ities of c-Abl toward each site. Therefore, we performed in vitro
quantitative radiometric assays ofa-syn phosphorylation by meas-
uring 32P incorporation from g-32P ATP and compared the KM of
c-Abl toward Y39 and Y125 using recombinant WT SH2-CD
c-Abl. We first used peptides as substrates: a-syn (34–44) and
a-syn (119–129), spanning the Y39 and Y125 sites, respectively,
as well as a peptide from the canonical c-Abl substrate CrkL that
was used as a positive control and a point of reference. As shown
in Figure 1C, c-Abl displayed a higher affinity for the Y39
peptide (a-syn (34–44)) (KM¼ 56+11 mM) than for the Y125
peptide (a-syn(119–129)) (KM ¼ 246+52 mM), thus suggesting
a marked preference for phosphorylation at Y39 than at Y125
(Fig. 1C). The measuredKM andVmax values for thea-syn peptides
(Fig.1C)were inasimilar range to theCrkLpeptide, indicating that
a-syn can be considered as a good c-Abl substrate.
In order to take into account the possibility that the binding of
c-Abl to a-syn could involve amino acid residues that are distant
from the phosphorylation sites, we also performed in vitro
kinase assays using recombinant full-length (FL) a-syn as sub-
strate and FL human CrkII as a reference. These experiments con-
firmed that Y39 is the main c-Abl phosphorylation site in FLa-syn
because the Y39F mutant showed limited signals (Fig. 1D). These
findings demonstrated that c-Abl is a reasonably efficient kinase
that phosphorylates a-syn: although the well-known c-Abl
substrate CrkII (50) was more efficiently phosphorylated by
SH2-CD c-Abl than a-syn (Supplementary Material, Fig. S2A).
However the range in protein concentration to obtain signal was
comparable between the two proteins (Supplementary Material,
Fig. S1A). It is worth mentioning that the high protein concentra-
tions required to obtain good signals compared with the peptide-
based experiments (Fig. 1C) could possibly be explained by a
decreased accessibility of the phosphorylation sites owing to sta-
bilization of the intramolecular C- and N-terminal interactions
of monomeric a-syn (51) or formation of a-syn oligomers.
c-Abl-mediated a-syn phosphorylation at Y39 was also
confirmed using real-time nuclear magnetic resonance (NMR)
spectroscopy performed at pH 6.8 (Fig. 1E) and pH 7.4
(Supplementary Material, Fig. S2B). 15N-labeled WT a-syn
was co-incubated with recombinant c-Abl, and phosphorylation
at Y39 was measured in real time through the sequential acquisi-
tion of short (1 h) 1H–15N HSQC spectra (Fig. 1E and Supple-
mentary Material, Fig. S2B), where the appearance of new
cross-peaks for residues L38 and G41 (among others) reports on
the phosphorylation at Y39. Maximum phosphorylation was
achieved within 3–4 h with a final conversion estimated at 70–
80% (Fig. 1F). No clear spectral changes were observed for resi-
dues near Y125, suggesting little or nophosphorylation at this site,
but the relevant region of the spectrum was highly crowded, so a
definitive conclusion is not possible based solely on the present
NMR data. Together, these data provide strong evidence that
a-syn is a good substrate for c-Abl and that Y39 is the major phos-
phorylation site, while the extent of Y125 phosphorylation
remained low under these in vitro conditions.
Both Y39 and Y125 residues are phosphorylated
in human PD brains and in a-syn tg mice
Next, we sought to determine whether phosphorylation ofa-syn
at Y39 occurs in vivo, and we further explored the relationship
between c-Abl and a-syn in healthy and PD human brains. The
anterior cingulate cortex was chosen for analysis, as this
region has been shown to have increased a-syn phosphorylation
at the first indication of Lewy Body pathologies in the olfactory
bulb and substantia nigra (52), with the degree of phosphoryl-
ation correlating with the severity of Lewy body formation
(53). This region has limited cell loss in PD and can therefore
be structurally compared with control tissue. In addition to
detecting phosphorylated forms of a-syn (including pY39,
pY125 and pS129 as a positive marker for PD caes), we also
assessed and compared the levels of c-Abl in PD brains and age-
matched control cases (Fig. 2 and Table 1).
The phosphorylation levels (pS129, pY125 and pY39) ofa-syn
were evaluated using WB (Fig. 2A, left panel; shown, n ¼ 7 from
PD cases and n ¼ 7 from age- and post-mortem delay-matched
neurological and neuropathological controls) and quantified by
densitometry (n ¼ 17 from PD cases and n ¼ 17 from control
samples) (Fig. 2A, right panel). pY125 and pY39 were detected
at similar levels in the anterior cingulate cortex from PD (n ¼
17) and age- and post-mortem delay-matched neurological and
neuropathological controls (n ¼ 17), whereas, as expected,
pS129 was detected only in PD cases (Fig. 2A).a-syn phosphory-
lated at Y39 and/or Y125 was detected only in the sodium dodecyl
sulfate (SDS) soluble fraction of the anterior cingulate cortex and
putamen from PD cases (Fig. 2B).
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Figure2.Phosphorylation ofa-syn at Y39 and Y125 and an increase in c-Abl protein level can be detected in vivo in human PD brain tissue. (A) Representative WB of
the relative phosphorylation status of a-syn observed in PD cases versus controls. Protein extracts from samples of the anterior cingulate cortex from Parkinson’s
disease patients (n ¼ 17) and age- and post-mortem delay-matched neurological and neuropathological controls (n ¼ 17) were resolved by SDS–PAGE and analyzed
by WB (shown, n ¼ 7 from PD cases and n ¼ 7 from age- and post-mortem delay-matched neurological and neuropathological controls) using a-syn antibodies
against pS129, pY125, pY39 and total a-syn (left-hand-side panel). Phosphorylation levels (pS129, pY125, pY39) of a-syn were evaluated by densitometry quan-
tification (right-hand-side panel). The band intensities were normalized in the following manner: [(pY39 or pY125 or pS129/actin)/a-syn]. The bars represent the
mean+SD of PD cases (n ¼ 17) and control cases (n ¼ 17). ∗∗P , 0.005; (Student’s t-test: PD cases versus controls). (B) Representative WB of the relative
amounts of a-syn in PD cases. The brain tissue (anterior cingulate cortex that has lots of Lewy bodies (lanes 1 and 3) and putamen where the dopamine terminals
are lost (lanes 2 and 4) from PD cases was sequentially extracted for TBS-soluble and SDS-soluble fractions. Proteins were resolved by SDS–PAGE and analyzed
by WB usinga-syn antibodies against pY125, pY39 and totala-syn. (C) Representative fixed tissue ICC showing protein immunoreactivity in PD and control cases.
c-Abl immunoreactivity was observed in small neuronal cytoplasmic punctate structures, which were enhanced in a proportion of pyramidal neurons in PD cases
versus controls.a-syn immunoreactive Lewy bodies were only observed in a proportion of pyramidal neurons in the PD cases. Scale bar ¼ 10 mm. (D) Representative
WB of the relative c-Abl protein amounts observed in PD cases versus controls. Protein extracts from samples of the anterior cingulate cortex from PD cases (n ¼ 17)
and age- and post-mortem delay-matched neurological and neuropathological controls (n ¼ 17) were resolved by SDS–PAGE and analyzed by WB (shown, n ¼ 10
from PD cases and n ¼ 10 from age- and post-mortem delay-matched neurological and neuropathological controls) using a c-Abl antibody (left hand panel). c-Abl
protein level was evaluated by densitometry quantification (right-hand-side panel). The band intensities were normalized in the following manner: (c-Abl/actin). The
bars represent the mean+SD of PD cases (n ¼ 17) and control cases (n ¼ 17). ∗P , 0.05; (Student’s t-test: PD cases versus controls).
2862 Human Molecular Genetics, 2014, Vol. 23, No. 11
Interestingly, IHC revealed c-Abl expression in small neuronal
cytoplasmic punctate structures, which were enhanced in a pro-
portion of pyramidal neurons in PD cases versus controls
(Fig. 2C, upper panel). To the best of our knowledge, this is the
first report showing the presence of c-Abl withina-syn aggregates
in human brain tissue from PD patients. WB (shown, n ¼ 10 from
PD cases and n ¼ 10 from age- and post-mortem delay-matched
neurological and neuropathological controls) and densitometry
quantification showed a slight, but significant, increase in c-Abl
protein levels in the anterior cingulate cortex from PD patients
(n ¼ 17) compared with age- and post-mortem delay-matched
neurological and neuropathological controls (n ¼ 17) (Fig. 2D).
These data are consistent with the recent findings of Hebron
et al., which showed an increase in c-Abl protein levels in the stri-
atum of brains from post-mortem PD patients (26).
The levels of c-Abl, pY39 and pY125a-syn proteins were also
assessed in tg mice overexpressing human WT a-syn under the
mThy1 promoter (mThy1-a-syn, Line 61) (54). These mice
develop behavioral motor deficits (40), axonal pathology and ac-
cumulation of a-syn cleaved at the C-terminus, and aggregate
within cortical and subcortical regions (55) mimicking the
pathological aggregates of PD/DLB (56,57). WB analysis of
membrane fractions of brain homogenates from non-tg and
a-syn WT tg mice revealed a significant increase in protein
levels of c-Abl, pY39 and pY125 a-syn as well as total a-syn
levels (Fig. 3A). However, cytosolic fractions did not show posi-
tive signals (Supplementary Material, Fig. S3A). Antibodies
against pY39 and pY125 a-syn displayed increased immunor-
eactivity in neurons in the deeper layers of the temporal cortex
(Fig. 3B, left hand panel). In some cases, the immunostaining
concentrated in the cytoplasm was mimicking inclusions
(Fig. 3B, left hand panel). Interestingly, c-Abl immunostaining
in pyramidal neurons in the neocortex was increased in the
a-syn tg mice compared with the WT mice (Fig. 3B, right
hand panel). Together, these data show that c-Abl levels are
increased in diseased human brains and in a mice model of PD.
c-Abl protein levels are transiently increased in a
rat genetic model of PD
The protein levels of c-Abl, pY39 and pY125 were then investi-
gated in rat midbrain in which a-syn has been overexpressed
using the AAV-delivery system in the substantia nigra (58,59)
(Fig. 4). Strikingly, 1 month after injection, c-Abl protein
levels were significantly increased in the soma and the neurites
of dopaminergic neurons within the substantia nigra overexpres-
sing a-syn (n ¼ 3, Fig. 4A and B). Similar observations were
made using three different antibodies raised against different
epitopes in c-Abl (Fig. 4A and B). Interestingly, c-Abl signal
was significantly reduced 3 months after injection (n ¼ 3,
Fig. 4A and B), suggesting that c-Abl expression is transiently
induced by the overexpression of a-syn. No positive signal
was detected in the non-injected side or in the control group
(FPmax-injected rats; Fig. 4A and B), suggesting that under
physiological conditions, c-Abl is expressed at low levels and/
or its levels are tightly regulated (8,26). The use of specific anti-
body against activated c-Abl (pY412) revealed that upon a-syn
overexpression the level of activated c-Abl was increased
(Fig. 4C, top panel). Moreover, an increase in pY39 a-syn
levels was also observed (Fig. 4C, bottom panel).
Taken together, these data demonstrate that a-syn overex-
pression induces a transient increase of c-Abl expression that
is associated with the accumulation of activated c-Abl and phos-
phorylated a-syn at Y39.
c-Abl induces a-syn phosphorylation at Y39
and Y125 in primary cortical neurons
Next, we investigated whether c-Abl could phosphorylate en-
dogenous a-syn at Y39 in primary cortical neurons.
Figure 5A demonstrates that endogenous mouse a-syn was
phosphorylated at Y39 and Y125. This basal phosphorylation
level at both residues was significantly increased in cortical
neurons after transduction with lentiviruses encoding WT
c-Abl (Fig. 5A). Phosphorylation of a-syn by c-Abl was then
examined using ICC (Fig. 5B). Primary cortical neurons (WT
and a-syn KO) were transduced with lentiviruses to express
WT c-Abl or KD c-Abl (an inactive form of c-Abl bearing the
K290R point mutation in the kinase domain). At 5 days post-in-
fection, c-Abl efficiently phosphorylated a-syn at Y39 and
Y125 residues in WT mouse cortical neurons (Fig. 5B). More-
over, the kinase-dead form of c-Abl (KD c-Abl) was not able to
phosphorylate WT a-syn (Supplementary Material, Fig. S3).
As expected, cortical neurons of a-syn KO mice showed no
immunoreactivity with the antibodies specific for either pY39
or pY125 a-syn (Fig. 5B and Supplementary Material,
Fig. S3B), further confirming the specificity of the antibodies
used in this study.
c-Abl induces a-syn phosphorylation at Y39
and Y125 in mammalian cells
For detailed biochemical analyses of the interplay between
a-syn and c-Abl, we used HEK293T, HeLa and the neuroblast-
oma cell line M17. We first characterized c-Abl-mediateda-syn
phosphorylation in these cell lines. As endogenousa-syn expres-
sion is hardly detectable by WB in these cell lines, HEK293T
cells were co-transfected with WT a-syn or mutants in which
one or multiple tyrosine residues were mutated from tyrosine
to phenylalanine (Y39F, Y125F and Y39F/Y125F) together
Table 1. Demographic details for PD and control cohorts
Diagnosis Sex (M:F) Age (years) PMD (h) Duration (years)
PD (n ¼ 17) 13:4 78.9+1.2 (69–88)a 18.3+3.2 (5–50)a 15.3+1.7 (7–33)
Control (n ¼ 17) 8:9 78.1+2.7 (60–97) 17.8+2.6 (5–36)
Values are given as mean+ standard error and range for age at death (age), post-mortem delay (PMD) and disease duration (duration).
aNot significantly different from control values (t-test, P . 0.05).
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with c-Abl or a control plasmid encoding luciferase (LUC). WB
(Fig. 6A and B) and ICC (Fig. 6C) analyses showed the phos-
phorylation of both Y39 and Y125 residues by c-Abl in
HEK293T cells. When WT or Y39F a-syn was expressed, we
observed only tyrosine phosphorylation at Y125. However,
when WT a-syn was coexpressed with c-Abl, a prominent
band was also detected using the anti-pY39 antibody. As
observed in cortical neurons, the kinase inactive form of c-Abl
(KD c-Abl) did not phosphorylate WT a-syn, whereas the con-
stitutively active form of c-Abl (bearing the P242E/P249E
double mutation; referred to as PP c-Abl) phosphorylates
a-syn more efficiently (almost a 2.5-fold increase) at Y39 and
Y125 compared with WT c-Abl (Fig. 6B). The ability of c-Abl
to phosphorylate a-syn at Y39 and Y125 was also confirmed
in HeLa (Supplementary Material, Fig. S4A and C) and M17
cell lines (Supplementary Material, Fig. S4B).
Modulation of c-Abl level or activity directly influences
the level of a-syn phosphorylation at Y39 and Y125
Our cell-based experiments confirmed that a-syn is a potential
physiologically relevant substrate for c-Abl. To confirm the speci-
ficity of c-Abl-mediateda-syn phosphorylation at Y39 and Y125,
we modulated c-Abl activity in cells through the downregulation
of c-Abl protein expression using siRNA or by pharmacological
inactivation or activation of c-Abl kinase activity.
We first validated the efficiency and specificity of the siRNAs
designed to downregulate c-Abl in HEK293T cells. As shown in
Figure 7A, 48 h after transfection, c-Abl siRNAs reduce the en-
dogenous c-Abl protein levels by 60%. The use of a Scramble
(Sc) siRNA sequence did not affect c-Abl protein levels, con-
firming the specificity of the designed c-Abl siRNA (Fig. 7A).
We then sought to investigate whethera-syn phosphorylation
induced by c-Abl overexpression could be attenuated by c-Abl
siRNA downregulation. As expected, when the level of c-Abl
overexpressed in HEK293T cells was downregulated to approxi-
mately endogenous c-Abl levels (Fig. 7A), the phosphorylation
of a-syn at Y39 and Y125 was nearly abolished (Fig. 7B).
We then assessed the effect of inhibiting c-Abl activity using
three highly specific c-Abl inhibitors: nilotinib, imatinib (ATP-
competitive kinase inhibitors) (60) and GNF-2 (allosteric c-Abl
inhibitor) (61). All three inhibiors strongly decreased a-syn
phosphorylation levels at Y39 and at Y125 (Fig. 7C). On the con-
trary, activation of endogenous c-Abl using the allosteric activa-
tor DPH (45) resulted in a marked increase in a-syn
phosphorylation at Y39 and Y125 in SH-SY5Y cells (Fig. 7D).
Figure 3. Both c-Abl and phosphorylated a-syn (at Y39 or Y125) levels are increased in a-syn transgenic mice. (A) Brain homogenates from non-transgenic and
mThy1-h a-syn WT transgenic (tg) mice from line 61 (49) (male, 6 m/o) were fractioned into membrane and cytosolic fractions and ran in SDS–PAGE gels,
blotted and probed with antibodies against pY125, pY39, a-syn, c-Abl and actin as previously described (54). Representative blots are from the membrane fraction,
bands in the far right are recombinantproteins that servedas positive controls and molecularweight markers (left-hand-side hand panels). Image analysis of the specific
bands expressed as ratio to the actin loading control. The bars represent the mean+SD of n ¼ 5 mice per group, ∗P , 0.001 by Student’s t-test. (B) Immunocyto-
chemical analysis with antibodies pY125, pY39, a-syn and c-Abl developed with diaminobenzidine utilizing vibratome sections. Images are representative of the
temporal cortex. In the tg mice, there was increased immunoreactivity in neuronal cell bodies with pY125, pY39, a-syn and c-Abl antibodies.
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Figure 4. c-Abl protein levels increase transiently upon a-syn overexpression in rat midbrains. (A and B) Effect of a-syn overexpression on c-Abl protein levels in
vivo, low magnification (scale bar: 500 mm) (A) and high-power magnification photomicrographs (scale bar: 100 mm) (B) that illustrate the endogenous protein level
of c-Abl after the overexpression of humana-syn or FPmax (∗, injected side;n ¼ 3 per condition). The use of three different antibodies raised against different epitopes
of c-Abl [(Sigma), (K12, Santa Cruz), (24-11, Santa Cruz)] revealed a dramatic increase of c-Abl protein level only in the side injected with humana-syn. Overexpres-
sion of a-syn was confirmed by IHC staining on serial section (B, bottom line). No c-Abl signal was detected in FPmax-injected or in the non-injected sides. The
enhancement of c-Abl protein expression induced by a-syn overexpression was primarily observed at 1 month post-injection and disappeared after 3 months
post-injection, suggesting a transient interplay between c-Abl and a-syn. (C) Protein levels of pY39 a-syn and activated c-Abl (pY412, a marker of high kinase ac-
tivity) increased only in the injected side overexpressing a-syn 1 month post-injection (scale bar: 50 mm).
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Figure 5. c-Abl inducesa-syn phosphorylation at Y39 and Y125 residues in primary cortical neurons. (A) WT primary cortical neurons were infected with lentivirus
encoding for c-Abl or with an empty lentivirus. Five days post-infection, neurons were lysed and the proteins were separated using SDS–PAGE and detected by WB
analysis (left-hand-side panel). Thea-syn phosphorylation status was assessed using the phosphorylation site-specific antibodies for Y39 or Y125 residues.a-syn and
c-Abl expressions were confirmed in an additional protein blot using specific antibodies. Actin was used as a loading control. The phosphorylation ofa-syn at residues
Y39 and Y125 was evaluated by densitometry quantification (right-hand-side panel). The band intensities were normalized in the following manner: pY39/[a-syn/
actin] or pY125/[a-syn/actin]. Bars represent the mean+SD of three independent experiments. ∗P , 0.05 (Student’s t-test: non-infected versus c-Abl infection). (B)
WT ora-syn KO primary cortical neurons were infected with c-Abl lentivirus or an empty lentivirus. Five days post-infection, neurons were immunostained with the
appropriate antibodies and counterstained with DAPI to reveal the nucleus.
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Figure 6. c-Abl inducesa-syn phosphorylation at Y39 and Y125 residues in HEK293T cells. (A) HEK293T cells were transfected with WTa-syn or its mutants (Y39F,
Y125F or Y39FY125F) together with plasmids encoding for LUC (negative control) or WT c-Abl. Twenty-four hours post-transfection, cells were lysed and the proteins
separated using SDS–PAGE and detected by WB analysis (top panel).a-syn phosphorylation status was assessed using phosphorylation site-specific antibodies for Y39
or Y125 residues.a-syn and c-Abl expression were confirmed in an additional protein blot using specific antibodies. Actin was used as a loading control. The phosphor-
ylation ofa-syn at residues Y39 and Y125 was evaluated by densitometry quantification (bottom panel). The band intensities were in the following manner: pY39/[a-syn/
actin] or pY125/[a-syn/actin]. The bars represent the mean+SD of three independent experiments. ∗∗P, 0.005; ∗∗∗P, 0.0005 (Student’s t-test:a-syn + LUC versus
a-syn + c-Abl). (B) HEK293T cells were transfected with WTa-syn or its mutants (Y39F, Y125F or Y39FY125F) together with plasmids encoding for WT c-Abl or its
inactive mutant KD c-Abl (kinase dead) or its constitutively active mutant PP c-Abl. Twenty-four hours post-transfection, cells were lysed and proteins separated using
SDS–PAGE and detected by WB analysis (top panel).a-syn phosphorylation status was assessed using phosphorylation site-specific antibody for Y39 or Y125 residues.
a-synandc-Ablexpressionwereconfirmed inanadditionalproteinblotusingspecificantibodies.Actinwas usedasa loadingcontrol.Phosphorylationofa-synat residues
Y39 and Y125 was evaluated by densitometry quantification (bottom panel). The band intensities were normalized as followed: pY39/[a-syn/actin] or pY125/[a-syn/
actin]. The bars represent the mean+SDof three independentexperiments. ∗∗P, 0.005; ∗∗∗P, 0.0005 (Student’s t-test:a-syn + KD c-Abl versusa-syn + WTc-Abl
or PP). (C) HEK293T cells were transfected with WT a-syn together with plasmids encoding for LUC or WT c-Abl. Twenty-four hours post-transfection, cells were
immunostained with the appropriate antibodies and counterstained with DAPI to reveal the nucleus.
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Figure 7. Modulation of c-Abl activity regulates a-syn phosphorylation at Y39 and Y125 residues. (A) Validation of the siRNA against c-Abl. HEK293T cells were
transfected with specific siRNA against c-Abl or with a negative control (scramble siRNA, Sc). Forty-eight hours post-transfection, cells were lysed and protein level
of endogenous c-Abl was assessed by WB and quantified by densitometry. The band intensities were normalized in the following manner: c-Abl/actin. The bars represent
the mean+SD of four independent experiments. ∗∗∗P, 0.005 (Student’s t-test: siRNA Sc cells versus siRNA c-Abl cells). (B) Downregulation of c-Abl protectsa-syn
from phosphorylation at Y39 and Y125 residues. HEK293T cells were transfected with a siRNA construct against c-Abl or with a control scrambled siRNA (Sc) together
with plasmids encoding for WT a-syn and WT c-Abl. The downregulation of the c-Abl protein and its effect on a-syn phosphorylation (Y39 and Y125 residues) was
confirmed by WB 48 h post-transfection (left-hand-side panel). Actin was used as a loading control. a-syn phosphorylation at Y39 and Y125 was evaluated by densi-
tometry quantification (right-hand-side panel). The band intensities were normalized in the following manner: c-Abl/actin or pY39/[a-syn/actin] or pY125/[a-syn/
actin]. The bars represent the mean+SD of three independent experiments. ∗P, 0.01; ∗∗P, 0.005 (Student’s t-test: siRNA Sc cells versus siRNA c-Abl cells).
(C) c-Abl drug inhibitors protect a-syn from phosphorylation at Y39 and Y125 residues. c-Abl activity can be specifically inhibited using drugs such as nilotinib and
imatinib (ATP competitors) or GNF-2 (non-ATP competitor). HEK293T cells were transfected with WTa-syn together with a plasmid encoding for WT c-Abl. Twenty-
fourhourspost-transfection, thecells were leftuntreated(DMSO) or treatedovernightwithc-Ablkinasepharmacological inhibitors:nilotinib(20 mM) or imatinib(20 mM)
or GNF-2 (20 mM). WB analysis (top panel) shows the decrease ofa-syn phosphorylation (Y39 and Y125 residues) when c-Abl activity was inhibited using drugs. Actin
was used as a loading control. The phosphorylation ofa-syn at residues Y39 and Y125 was evaluated by densitometry quantification (bottom panel). The band intensities
were normalized in the following manner: pY39/[a-syn/actin] or pY125/[a-syn/actin]. The bars represent the mean+SD of three independent experiments. ∗P, 0.05;
∗∗P, 0.005 (Student’s t-test: untreated versusc-Abl kinasedrug inhibitors). (D) c-Abl drugactivator DPH inducesa-syn phosphorylationatY39andY125 residues inan
SH-5Y5a-syn stable cell line. SH-5Y5a-syn stable cells were left untreated (DMSO) or treated for 3 h with DPH (50 mM) and analyzed by WB (top panel). DPH induced
a-syn phosphorylation at Y39 and Y125 residues was evaluated by densitometry quantification (bottom panel). The band intensities were normalized in the following
manner: pY39/[a-syn/actin] or pY125/[a-syn/actin]. The bars represent the mean+SD of three independent experiments. ∗P, 0.05 (Student’s t-test: untreated versus
DPH treatment). (E) c-Abl drug activator induces a-syn phosphorylation at Y39 and Y125 residues. c-Abl activity can be specifically activated using DPH. HEK293T
cells were transfected with a siRNA construct against c-Abl or with a control scrambled siRNA (Sc). Twenty-four hours post-transfection, cells were left untreated
(DMSO) or treated overnight with c-Abl kinase drugs activator: DPH (50 mM) with or without imatinib (20 mM). Immunoblots (top panel) shown that DPH induced phos-
phorylation of a-syn (Y39 and Y125 residues) in the cells expressing c-Abl (Sc cells) but not in the cells in which endogenous c-Abl has been downregulated. Imatinib
inhibited phosphorylation of a-syn (Y39 and Y125 residues) induced using DPH in the Sc cells. Phosphorylation of a-syn at residues Y39 and Y125 was evaluated by
densitometry quantification (bottom panel). The band intensities were normalized in the following manner: pY39/[a-syn /actin] or pY125/[a-syn/actin]. The bars rep-
resent the mean+SD of three independent experiments. ∗∗P, 0.005 (Student’s t-test: siRNA Sc cells versus siRNA c-Abl cells).
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DPH was also able to induce a-syn phosphorylation at Y39 and
Y125 residues in HEK293T transfected with Scramble siRNA
(Sc) (Fig. 7E). However, when endogenous c-Abl was downre-
gulated using specific siRNA, the effect of DPH on a-syn phos-
phorylation was abolished (Fig. 7E). Interestingly, the effect of
DPH on a-syn phosphorylation level in HEK293T cells expres-
sing endogenous c-Abl (Sc cells) was inhibited using imatinib
(Fig. 7E).
Together, these experiments show thata-syn phosphorylation
at Y39 and Y125 can be modulated by regulating c-Abl tyrosine
kinase activity using specific inhibitors and activators.
c-Abl interacts with a-syn in primary cortical neurons
and in HEK 293T
To determine whether c-Abl directly interacts with a-syn, we
performed coimmunoprecipitation experiments of endogenous
c-Abl and a-syn using lysates from primary cortical neurons.
As shown in Figure 8A, c-Abl was detected in a pull-down of en-
dogenous a-syn. The interaction between a-syn and c-Abl was
also confirmed in HEK293T cells co-overexpressing both pro-
teins by immunoprecipitation of either a-syn or c-Abl (Fig. 8B
and E). The a-syn that was coimmunoprecipitated with c-Abl
was phosphorylated at Y39 and Y125 residues (Fig. 8B and E).
To validate this interaction using a complementary method,
we excised the SDS–PAGE band corresponding to c-Abl fol-
lowing immunoprecipitation of a-syn and subjected this
sample to tryptic digestion and LC-ESI-MS/MS analysis.
Figure 8C shows the sequence coverage for c-Abl, identified
from coimmunoprecipitation (right hand panel), and the MS/
MS spectrum of a unique c-Abl-specific tryptic peptide (left
hand panel). The phosphorylation of a-syn by c-Abl was also
confirmed using MS (Fig. 8D). As described above, a-syn was
immunoprecipitated from HEK293T cells co-transfected with
c-Abl or a control plasmid encoding LUC. The immunoprecipi-
tates were separated using SDS–PAGE, and the bands corre-
sponding to a-syn and c-Abl were excised, digested with
trypsin and analyzed by LC–ESI–MS/MS. Figure 8D shows
the sequence coverage and a representative MS/MS spectrum
confirming a-syn phosphorylation at Y39 residue. Under these
conditions, we could not detect any a-syn phosphorylation at
the Y125 residue. WB of the immunoprecipitates pulled down
using an anti-c-Abl antibody confirmed the interaction with
a-syn (Fig. 8E). Moreover, co-immunoprecipitations of a-syn
with the c-Abl kinase-dead mutant (KD c-Abl) revealed a lack
of interaction between the two proteins, showing that a
kinase-active conformation is needed for the interaction
(Fig. 8F). Interestingly, mutating Y39, Y125 or both residues
to phenylalanine in a-syn did not affect its interaction with
c-Abl but only its phosphorylation status (Fig. 8G).
Phosphorylation of a-syn by c-Abl protects against its
degradation via the autophagy and proteasome
pathways in cortical neurons
To further explore the relationship betweena-syn and c-Abl and
particularly the mechanisms by which c-Abl expression and/or
activation might influence the pathogenicity of a-syn in PD,
we investigated the consequences of overexpressing or
modulating the activity of c-Abl on a-syn expression levels
(mRNA and protein) and its clearance.
Hebron et al. have recently suggested a bidirectional relation-
ship betweena-syn and c-Abl in vivowhere an increase ofa-syn
protein level induces the phosphorylation of c-Abl and thereby
its activation, whereas an increase in the c-Abl protein level
and activity results in a-syn accumulation (26). In our hands,
the overexpression of a-syn in mouse primary cortical neurons
using lentiviruses did not induce any changes in c-Abl protein
levels (Fig. 9A). We also did not detect an increase in endogen-
ous a-syn expression following the infection of cortical neurons
with WT c-Abl lentiviruses (Fig. 9B). As expected, the infection
of cortical neurons using WT or PP c-Abl lentiviruses resulted in
a-syn phosphorylation at Y39 and Y125 residues (Figs 5 and
9B), whereas KD c-Abl had no effect ona-syn phosphorylation,
thus ruling out technical issues during the infection of the
neurons (Fig. 9A and B). However, in in vivo models in which
the a-syn protein level is increased such as in a-syn tg mice
(Fig. 3) or in rat midbrain overexpressinga-syn using the AAV-
delivery system (Fig. 4), a significant and marked increase in
c-Abl protein level (Figs 3B and 4A and B) could be observed.
In rat midbrain, the protein levels of c-Abl and activated c-Abl
(pY412) are increased (Fig. 4C). Until recently, the endogenous
protein levels of c-Abl have been shown to be increased only in
the brains of PD patients (26), whereas c-Abl expression in
healthy patients remains unchanged (12,13) or at low basal
levels (26). Together, these data demonstrate that a-syn over-
expression is able to induce the transient expression of c-Abl
in the midbrain, consistent with the recently published data of
Hebron et al. showing an increase of c-Abl protein levels
after the overexpression of a-syn in the substantia nigra of
mice (26).
Having confirmed that a-syn is phosphorylated at Y39 and
Y125 in human brain tissues (Fig. 2A and B), we sought to
better understand the physiological consequences of c-Abl-
mediated phosphorylation of a-syn. It has previously been
reported that phosphorylation ofa-syn at S129 regulates its clear-
ance via the proteasome (62) or the autophagy pathways (58).
Therefore, we sought to evaluate the neuronal protein levels of
a-syn when c-Abl was specifically inhibited. In cortical
neurons, a-syn protein levels were dramatically decreased when
c-Abl activity was inhibited using nilotinib (Fig. 10A), imatinib
or GNF-2 (Supplementary Material, Fig. S5A). c-Abl protein
levels were also decreased by nilotinib (Fig. 10A), imatinib or
GNF-2 (Supplementary Material, Fig. S5A) treatment. A semi-
quantitative RT-PCR assay ruled out any effect of the c-Abl inhi-
bitors on the mRNA levels of a-syn and c-Abl (Fig. 10B,
Supplementary Material, Fig. S5B). Interestingly, the effect of
nilotinib, the inhibitor showing the highest specificity toward
c-Abl inhibition (28), on the a-syn protein levels was counter-
acted by the proteasome inhibitor MG132 or two inhibitors of
autophagy, namely 3-methyladenine (3-MA) 3-MA (a Class III
PI 3-kinase inhibitor that inhibits autophagic sequestration at an
early stage of autophagy) and bafilomycin A1 (a vacuolar H+-
ATPase inhibitor that blocks late stage autophagy by inhibiting
autophagosome fusion to endosomes or lysosomes) (Fig. 10C).
However, an inhibitor of lysosomal pathways (NH4Cl) did not
rescue a-syn protein levels after nilotinib treatment (Fig. 10C).
The protection of c-Abl from nilotinib-induced degradation
was primarily observed upon treatment with bafilomycin A1
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Figure 8. c-Abl interacts witha-syn. (A) Co-immunoprecipitation of endogenous/nativea-syn and c-Abl. Cortical neurons were lysed and total cell lysates were left
untreated (Ctrl without IgG, Input) or immunoprecipitated (IP) with an anti-a-syn antibody and the blots were probed with the indicated antibodies. WB showed that
endogenous c-Abl could be co-immunoprecipitated with endogenousa-syn. (B–D) Mass spectrometry-based confirmation of c-Abl-mediateda-syn phosphorylation
at Y39. HEK293T cells were transfected with WT a-syn together with plasmids coding for Luciferase or WT c-Abl. Twenty-four hours post-transfection, total cell
lysates were left untreated (Ctrl without IgG, Input) or immunoprecipitated (IP) with an anti-a-syn antibody, and the blots were probed with the indicated antibodies.
(B) WB analysis confirmed a-syn phosphorylation at Y39 and Y125 residues and showed c-Abl could be co-immunoprecipitated with a-syn (top panel). IP eluates
were also loaded onto Coomassie-stained gels and the bands corresponding toa-syn and c-Abl were excised, digested with trypsin and analyzed by LC–ESI–MS/MS.
(C) Sequence coverage for c-Abl identified from the Co-immunoprecipitation, and the MS/MS spectrum of a unique, c-Abl-specific tryptic peptide (sequence
GGEEEGGGSSS, indicated by a red frame). (D) The sequence coverage and a representative MS/MS spectrum confirming a-syn phosphorylation at Y39 (figures
generated using Scaffold v. 3.4.5). (E) a-syn co-immunoprecipitated with c-Abl. HEK293T cells were transfected with WT a-syn together with plasmids encoding
for WT c-Abl. Twenty-four hours post-transfection total cell lysates were left untreated (Ctrl without IgG, Input) or immunoprecipitated (IP) with an anti-c-Abl anti-
body and the blots probed with the indicated antibodies. (F) WT c-Abl but not its inactive mutant (KD c-Abl) Co-immunoprecipitated witha-syn. HEK293T cells were
transfected witha-syn WT together with plasmids encoding for WT c-Abl or KD c-Abl. Twenty-four hours post-transfection total cell lysates were left untreated (Ctrl
without IgG, Input) or IP with an anti-a-syn antibody and blots probed with the indicated antibodies. (G) WT c-Abl co-immunoprecipitated with WT a-syn or its
mutants. HEK293T cells were transfected with WT a-syn or its mutant (Y39F, Y125F or Y39FY125F) together with plasmid encoding for WT c-Abl. Twenty-four
hours post-transfection total cell lysates were left untreated (Ctrl without IgG, Input) or IP with an anti-a-syn antibody, and blots probed with the indicated antibodies.
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(Fig.10C). Taken together, these results suggest that the inhibition
of c-Abl activity leads to the degradation of a-syn via autophagy
pathways.
DISCUSSION
a-syn is a physiologically relevant substrate for c-Abl
The increased expression or aberrant activation of the tyrosine
kinase c-Abl has been implicated in the pathogenesis of PD
(12,13,26) and other neurodegenerative diseases (8). In the
context of PD, c-Abl-mediated phosphorylation of parkin was
shown to inhibit the ubiquitin ligase activity and neuroprotective
functions of parkin in primary neuron cultures and in animal
models of PD (12,13). The inhibition of c-Abl using imatinib
restores the activity and neuroprotective function of parkin. Re-
cently, Hebron et al. showed that the pharmacological inhibition
of c-Abl promotes the autophagic clearance ofa-syn and protects
againsta-syn-induced loss of dopaminergicneurons ina lentiviral
mouse model of synucleinopathies (26,43). However, the role of
c-Abl-mediated a-syn phosphorylation in these processes was
not known.
Herein, using multiple biophysical and biochemical
approaches, we established that c-Abl directly interacts with
a-syn and phosphorylates it mostly at Y39 in vitro (Fig. 1),
and in vivo in primary cortical neurons (Fig. 5) and in mamma-
lian cell lines (Figs 6–8). The inhibition of c-Abl activity in
cells either by downregulating directly its expression and
protein level using siRNA or by inhibiting its kinase activity
using specific c-Abl inhibitors such as imatinib, nilotinib or
GNF-2 resulted in a strong reduction (90%) of Y39 a-syn
phosphorylation (Fig. 7C). Conversely, the activation of en-
dogenous c-Abl using DPH induces a-syn phosphorylation at
Y39 and Y125 (Fig. 7D and E). These results further demonstrate
that a-syn is a bona fide substrate for c-Abl.
To explore the relationship between c-Abl and a-syn, and to
determine how the interaction between these proteins and Y39
phosphorylation might contribute to the pathogenesis of PD,
we assessed and compared the levels of c-Abl, a-syn and Y39
phosphorylation in the brains of PD patients and age-matched
controls (Fig. 2). Our results demonstrate for the first time that
a-syn phosphorylated at Y39 can be detected in human brain
tissues (Fig. 2A and B). However, we did not observe any signifi-
cant differences in the levels of pY39 and pY125 between PD
brains and controls, although c-Abl protein levels were upregu-
lated in PD brains (Fig. 2D). The presence of c-Abl in structures
positive for a-syn (Fig. 2C) suggests that the c-Abl interaction
and phosphorylation of a-syn might play a role in LB formation
and/or the regulation of the pathophysiological properties of
a-syn in PD. The investigation of the interplay between a-syn
and c-Abl in a rat model of PD also revealed that a-syn overex-
pression induces a transient induction of c-Abl expression
(Fig. 4). All together, these data suggest that c-Abl expression
and the accumulation of pY39 could play an important role in
modulating a-syn toxicity in vivo.
c-Abl and a-syn expression levels are concomitantly
regulated: implications for a-syn protein clearance during
PD progression
To further explore the interactions between c-Abl anda-syn and
gain insights into the mechanisms by which c-Abl expression
and/or activation might influence the pathogenicity of a-syn in
PD, we investigated the consequences of the overexpression of
c-Abl or the enhancement or the inhibition of its kinase activity
on the expression and clearance of a-syn. Our results confirmed
Figure9.a-syn protein level does not increase in cortical neurons infected by c-Abl. (A) Cortical neurons were infected with lentiviruses for GFP ora-syn (top panel).
After 5 days, neurons were lysed in Laemmli buffer 2× and the proteins were separated using SDS–PAGE. The expression levels ofa-syn and c-Abl were assessed by
WB. Actin was used as a loading control. c-Abl protein level was evaluated by densitometry quantification (bottom panel). The band intensities were normalized in the
following manner: (c-Abl/actin). The bars represent the mean+SD of three independent experiments. P. 0.05 (Student’s t-test: GFP versus a-syn infected cells).
(B) Cortical neurons were infected with lentiviruses for GFP, WT, KD or PP c-Abl. After 5 days, cells were lysed in Laemmli buffer 2× and the proteins were separated
by SDS–PAGE.a-syn and c-Abl expression levels were assessed by WB (left hand panel).a-syn phosphorylation status was also confirmed using anti-pY39 or pY125
antibodies in a separate protein blot. Actin was used as a loading control. The a-syn protein levels were evaluated by densitometry quantification (right-hand-side
panels). The band intensities were normalized in the following manner: (a-syn/actin). The bars represent the mean+SD of three independent experiments. P .
0.05 (Student’s t-test:GFP versus c-Abl infected cells); ∗P , 0.05 (Student’s t-test: GFP versus WT or PP c-Abl infected cells).
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previous findings demonstrating that nilotinib induces a-syn
protein degradation (Fig. 10A), and that this effect could be
reversed when nilotinib is combined with specific inhibitors of
autophagy such as 3-MA and Bafilomycin A1, and also using
MG132, a proteasome inhibitor (Fig. 10C). Interestingly, not
only a-syn protein level decreased in the presence of nilotinib,
but c-Abl itself is also targeted for degradation via the autophagy
pathway (Fig. 10C). In addition, our results showed that the
Figure 10. a-syn and c-Abl protein levels are concomitantly regulated via autophagy. (A) Inhibition of c-Abl activity by nilotinib induces degradation of a-syn and
c-Abl in primary cortical neurons. Primary cultures of cortical neurons were treated with nilotinib or DMSO (negative control). After 16 h of treatment, cells were
directly lysed in 2× Laemmli buffer and the proteins were separated using SDS–PAGE and detected by WB analysis using the appropriate antibodies (left-hand-side
panel). Actin was used as a loading control. c-Abl and a-syn protein level were evaluated by densitometry quantification (right-hand-side panels). Band intensities
were normalized as in the following manner: (c-Abl/actin) or (a-syn/actin). Bars represent the mean+SD of three independent experiments. ∗P , 0.05 (Student’s
t-test: DMSO versus nilotinib treatment). (B) Inhibition of c-Abl activity by nilotinib does not change mRNA levels of a-syn and c-Abl. Primary cultures of cortical
neurons were treated with nilotinib or DMSO (negative control). 16 h post-treatment, cells were lysed and mRNA extraction performed. Semiquantitative RT–PCR
using specific primers against c-Abl or a-syn followed by agarose gel electrophoresis (left hand panel) demonstrates that c-Abl and a-syn mRNA levels were not
changed upon nilotinib treatment. c-Abl and a-syn mRNA level were evaluated by densitometry quantification (right-hand-side panels). The band intensities
were normalized using the mRNA level of the housekeeping gene GAPDH: c-Abl/GAPDH ora-syn/GAPDH. The bars represent the mean+SD of three independent
experiments. P . 0.05 (Student’s t-test: DMSO versus nilotinib). (C) Inhibition of c-Abl activity by nilotinib induces degradation of a-syn and c-Abl via the autop-
hagy and proteasome pathways. Primary cultures of cortical neurons were treated with nilotinib or DMSO (negative control) for 16 h prior to addition of inhibitors of
autophagy(3-MA,Bafilomycin A1), an inhibitorof phagosome-lysosome fusion (NH4Cl) oran inhibitorof proteasome (MG-132) for6 h. The cells weredirectly lysed
in 2× Laemmli buffer and proteins were separated using SDS–PAGE and detected by WB analysis using the appropriate antibodies (left-hand-side panels). Actin was
used as a loading control. c-Abl anda-syn protein levels were evaluated by densitometry quantification (right-hand-side panels). The band intensities were normalized
in the following manner: (c-Abl/actin) or (a-syn/actin). The bars represent the mean+SD of three independent experiments. ANOVA test followed by Tukey–
Kramer post hoc test were performed: #P , 0.05 (DMSO versus nilotinib) or ∗P , 0.05 (nilotinib+drugs inhibitors).
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overexpression ofa-syn in rat midbrain induces a transient upre-
gulation of c-Abl protein level and activity (Fig. 4). These results
are in agreement with the recent findings of Hebron et al. (26).
Together, our findings suggest that c-Abl-mediated phosphor-
ylation and/or interaction with a-syn plays important roles in
stabilizinga-syn by suppressing its clearance via the autophagic
and the proteasomal pathways.
Increasing evidence suggests that the tyrosine kinase activity
of c-Abl plays important roles in regulating the clearance of
key proteins involved in PD or AD and represents a viable
target for the treatment of these neurodegenerative disorders.
The inhibition of c-Abl activity using different pharmacological
inhibitors reduces neurodegeneration in animal models of PD
(12,13,26,29). Nilotinib targets not only a-syn but also hyper-
phosphorylated tau for degradation (26). Imatinib, a first-
generation c-Abl inhibitor, has also been shown to act as a
powerful activator of autophagy in cells (63), and it inhibits
b-amyloid production in rat neuronal primary cultures and in
guinea pig brains (64). Further studies are needed to explore
the molecular mechanisms underlying the role of c-Abl in regu-
lating the production, clearance and aggregation of these pro-
teins and to validate c-Abl as a target for the treatment of PD
and related synucleinopathies.
MATERIALS AND METHODS
Reagents and antibodies
Monoclonal anti-a-syn and monoclonal anti-pY125 were pur-
chased from BD Biosciences (Switzerland). Monoclonal
b-actin was from Abcam (Switzerland). Anti-c-Abl (K12),
anti-c-Abl (24-11), anti-a/g/b-syn (N19) and anti-a-syn (211)
were obtained from Santa Cruz (Switzerland). Rabbit anti-c-Abl
was purchased from Sigma (Switzerland). Custom polyclonal
pY39 (raised against the synthetic peptide: K E G V L Y(p) V
G S K T K) and polyclonal pY125 were purchased from
Eurogentec (Belgium). Monoclonal c-Abl was a gift from
Prof. Oliver Hantschel (ISREC Institute, Ecole Polytechnique
Fe´de´rale de Lausanne (EPFL), Switzerland). The polyclonal
p62 and LC-3 antibodies were a gift from Prof. Darren Moore
(EPFL, Switzerland). FL a-syn rabbit polyclonal was from
Millipore (Temecula, CA, USA). Secondary antibodies
donkey antimouse Alexa647, donkey antirabbit IgG Alexa568,
donkey antigoat Alexa488 and goat antirabbit Alexa680 were pur-
chased from Life Technologies (Switzerland). The secondary
antibody goat antimouse IgG IRDye800CW was obtained from
Li-Cor Biosciences GmbH (Germany). The secondary anti-
body antiguinea pigHRP was a gift from Prof. Darren Moore
(EPFL, Switzerland). DPH (5-[3-(4-fluorophenyl)-1-phenyl-
1H-pyrazol-4-yl]-2,4-imidazolidinedione; c-Abl activator used
at a final concentration of 50 mM) 3-MA (3-methyladenine,
autophagy inhibitor; used at a final concentration of 10 mM)
and NH4Cl (lysosomal inhibitor; used at a final concentration
of 25 mM) were purchased from Sigma-Aldrich (Switzerland).
MG-132 (proteasome inhibitor; used at a final concentration of
20 mM) and Bafilomycin A1 (autophagy inhibitor; used at a
final concentration of 200 nM) were from Enzo Life Sciences
(Switzerland). The c-Abl inhibitors: nilotinib (used at a final con-
centration of 20 mM), imatinib (used at a final concentration of
20 mM) and GNF-2 (used at a final concentration of 20 mM)
were kindly provided by Prof. Oliver Hantschel (ISREC Insti-
tute, EPFL, Switzerland).
DNA constructs
Mammalian expression vectors encoding for WT c-Abl, the
catalytically inactive mutant of c-Abl (KD c-Abl; K290R) and
the constitutively active mutant of c-Abl (PP c-Abl; P242E/
P249E) were kindly donated by Prof. Oliver Hantschel
(ISREC Institute, EPFL). WT c-Abl, KD c-Abl, PP c-Abl, WT
a-syn and GFP were subcloned into the SIN-cPPT-PGK-WHV
gateway lentiviral vector kindly provided by Prof. Nicole
De´glon (UNIL, Switzerland). Human a-syn was subcloned
into the pAAV-CMV vector and the a-syn PD mutants (A30P,
E46K, A53T) inserted in the pCDNA6 vector were kindly pro-
vided by Prof. Aebischer (Brain Mind Institute, EPFL, Switzer-
land).
Mass spectrometry
For MS-based analytical phosphorylation assays, 100 mM of
WT, Y39F or Y125F a-syn were incubated with 5 mg of recom-
binant c-Abl in 50 ml of 20 mM Tris, 5 mM MgCl2, 1 mM DTT,
1 mM Na3VO4 and 25 mM NaF, pH 7.5, in the presence of
1 mM ATP. Reactions were performed overnight (16 h) at
308C without agitation. The reaction products were analyzed
as intact proteins (i.e. without proteolytic digestion) using
LC–ESI–MS on a Thermo LTQ ion trap system and SDS–
PAGE/western blotting with primary antibodies indicated
where appropriate.
In vitro kinase assays
Recombinant SH2-CD c-Abl kinase was overexpressed and puri-
fied fromE.coli as previously described (65). A total of 100 ng of
enzyme was incubated with different biotinylated peptides [CrkL
(Y207) peptide: biotin-EPAHAYAQPQTT-amide (calculated
Mw: 1538.40 Da, observed Mw: 1537.6 Da), a-syn (Y39):
biotin to be replaced by - instead of the underscore KEGV-
LYVGSKT, a-syn (Y125): biotin2DPDNEAYEMPS], at
various concentrations in the presence of 25 mM ATP for 20 min
at room temperature essentially as previously described (66).
For the assays employing FL proteins, recombinant WT and
Y39F a-syn were expressed in BL21(DE3) E. coli as previously
described (67) using a denaturing protocol, with an additional
reversed-phase HPLC purification step at the end of the experi-
ment, using a Proto 300 C4 column (20 mm ID × 250 mm
length, 5 mm particles) and a gradient from 30 to 60% B over
35 min at 15 ml/min, where solvent A was 0.1% TFA in water
and solvent B was 0.1% TFA in acetonitrile. The organic sol-
vents were removed from pooled pure fractions under vacuum
using a rotary evaporator and the proteins were subsequently lyo-
philized and stored at 2208C until use.
For the purification of recombinant CrkII, E. coli cells har-
vested from a 2 l culture expressing his-tagged, FL human
CrkII were lysed in in 100 ml Ni-NTA binding buffer (50 mM
Tris–HCl, pH 7.5, 500 mM NaCl, 5% glycerol, 25 mM imid-
azole) using a French press. The lysate was cleared by centrifu-
gation at 14 000g, 45 min, 48C. The cleared lysate was incubated
with 1.5 ml Ni-NTA resin (Qiagen) for 2 h and then the slurry
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transferred in a gravity flow column (Bio-Rad, Hercules, CA,
USA). Beads were washed with 60CV of Ni-NTA binding
buffer; then the protein was eluted with the same buffer supple-
mented with 500 mM Imidazole and several 1.5 ml fractions
were collected. After SDS–PAGE analysis, the most concen-
trated fractions were pooled and further purified. The protein
was dialyzed against TEV reaction buffer (50 mM Tris, pH 7.5,
150 mM NaCl, 5% glycerol, 0.5 mM EDTA, 1 mM DTT), then
the TEV protease was added at a 1:30 mass ratio and the cleavage
reaction proceeded overnight. To purify the TEV cleaved
protein, a reverse Ni-NTA purification was performed similarly
to previous step. The flowthrough, containing the cleaved
protein, was collected and further purified on a HiLoad 26/60
Superdex 75 gel-filtration column (GE Healthcare) in 50 mM
Tris–HCl, pH 7.5, 200 mM NaCl, 10% glycerol, 1 mM DTT.
The main peak containing the CrkII protein was collected and
concentrated using 10 kDa MWCO Microcon spin concentra-
tors (Millipore) for the assay purposes.
Shortly before performing the kinase assays, lyophilized
a-syn proteins (WT and Y39F) were resuspended at an initial
concentration of about 2 mM in ice-cold, argon-sparged
100 mM Tris, 100 mM NaCl, pH 7.5. Note that the very high
protein concentration and TFA counterions resulted in a slight
pH drop, requiring manual pH adjustment to 7.5. Because of
the tendency of a-syn to self-associate, particularly at high con-
centration, these stock solutions were kept on ice at all times and
rapidly filtered through 100 kDa MWCO Microcon membranes
(Millipore) in order to ensure that the kinase assays substrates
were in a monomeric state (due to its unfolded nature, a-syn
behaves as an 50 kDa protein despite its molecular weight of
14.4 kDa, thus only a-syn monomers are able to cross the
100 kDa MWCO membrane). The phosphorylation reactions
were carried out at different substrate concentrations, similarly
to the assays that used short peptides as substrates as described
above. To terminate the reactions, SDS-containing Laemmli
sample buffer was added and samples were boiled at 958C for
5 min, and then resolved on 15% polyacrylamide SDS gels.
Gels were then stained overnight at room temperature with a col-
loidal Coomassie Blue solution, destained against several
changes of deionized water for 2 h, then dried under vacuum at
808C in a Bio-Rad gel dryer. Dried gels were subjected to auto-
radiography for a first quality control, thena-syn bands were cut,
and phosphorylation was quantified by solid-state scintillation
counting using a Beckman-Coulter LS6500 multipurpose scin-
tillation counter configured to measure 32P.
Nuclear magnetic resonance
Purified a-syn was obtained from E. coli BL21(DE3) cells trans-
fected with plasmids encoding WT a-syn grown in isotopically
supplemented minimal media according to previously described
protocols (68), purified as previously described (69) and lyophi-
lized. The lyophilized 15N-labeled protein was resuspended in
phosphorylation buffer (20 mM Tris, 10 mM MgCl2, 1 mM DTT,
pH 6.8) at a concentration of 100 mM and then 1 mM ATP and
10 mg SH2-CD c-Abl were added. Sequential 1 h 1H–15N
HSQC spectra were collected overnight at 158C on a Bruker
AVANCE 500 MHz spectrometer. The relative intensity of the
peaks arising from unphosphorylated and phosphorylated protein
was calculated and plotted for well-resolved resonances
corresponding to residues in sequential proximity to Y39 (Leu38
and Gly41). All spectra were processed using NMRPipe (70)
and analyzed with NMRView (71).
Human brain tissue samples
Samples of the anterior cingulate cortex from longitudinally fol-
lowed, autopsy-confirmed subjects with PD (n ¼ 17; Table 1)
and age- andpost-mortemdelay-matched neurological andneuro-
pathological controls (n ¼ 17; Table 1) were obtained from the
Sydney Brain Bank and New South Wales Tissue Resource
Centre following study approval and with appropriate institution-
al ethics approval. All PDcases were levodopa-responsive, had no
other neurodegenerative conditions and met the UK Brain Bank
Clinical Criteria for diagnosis of PD (38). The anterior cingulate
cortex was chosen for analysis as this region has been shown to
have increased a-syn phosphorylation at the first indication of
Lewy body pathologies in the olfactory bulb and substantia
nigra (10) with the degree of phosphorylation correlating with
the severity of Lewy body formation (11), and has limited cell
loss in PD and can therefore be structurally compared with
control tissue.
For protein fractionation, human tissue was homogenized in
homogenization buffer [0.32 M sucrose, 20 mM Tris–HCl, pH
7.4, 5 mM EDTA, 1× protein inhibitor cocktail (EDTA free;
Roche) and 1× phosphatase inhibitor (Roche)], sonicated 2 ×
10 s on ice and then cleared by centrifugation at 16 000g for
10 min at 48C. The supernatant was labeled as the TBS-soluble
extract (TBS). The pellet was washed twice with homogenization
buffer, resuspended in homogenization buffer containing 5%
SDS, sonicated for 2 × 10 s and centrifuged at 100 000 g for
30 min at 248C. The supernatant was labeled as the SDS-soluble
fraction (SDS). All protein concentrations were determined
using the BCA method (Pierce).
For protein detection by WB analysis, 30–60 mg of
SDS-soluble protein samples were mixed with 5× Laemmli
buffer to obtain a final concentration of 1× per sample in a
total volume of 15–40 ml. The samples were denatured at
708C for 10 min and placed immediately on ice to stop further
denaturation of the proteins. The samples were subjected to elec-
trophoresis on 15 and 8% polyacrylamide SDS gels. After separ-
ation, the proteins were transferred onto nitrocellulose
membranes using the Bio-Rad Trans-Blot Turbo Transfer
System. The membranes were blocked with 5% powdered
skim milk in TBS-T (10 mM Tris–HCl, pH 7.5, 150 mM NaCl
and 0.05% Tween-20) for 1 h. The membranes were then
probed overnight using primary antibodies [rabbit polyclonal
anti-c-Abl (K-12), rabbit polyclonal anti-pY39-a-syn, rabbit
anti-pY125-a-syn, mouse monoclonal anti-a-syn and mouse
monoclonal anti-b-actin] diluted in blocking buffer. Finally,
the membranes were washed three times in TBS-T buffer and
probed with HRP-conjugated secondary antibodies diluted in
blocking buffer for 1 h at room temperature (goat antimouse
IgG-HRP and goat antirabbit IgG-HRP, Bio-Rad Laboratories).
Immunoreactivity was visualized by chemiluminescence using
an ECL detection system (GE Healthcare Biosciences) and cap-
tured using a Chemidoc imaging system (Bio-Rad).
For protein localization using ICC, 10 mm-thick formalin-
fixed paraffin-embedded tissue sections of the anterior cingulate
cortex were dewaxed and hydrated, followed by antigen retrieval
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in formic acid (90% formic acid for 3 min at room temperature).
After washing, the sections were blocked in 50% ethanol con-
taining 5% H2O2 for 1 h and then blocked in 5% BSA blocking
buffer (0.1% Triton X-100) for 2 h at room temperature. The sec-
tions were incubated in primary antibodies [rabbit polyclonal
anti-c-Abl (K-12) and mouse monoclonal anti-a-syn (BD)] pre-
pared in 1% BSA blocking buffer (0.02% Triton X-100) over-
night at 48C, followed by detection using an avidin–biotin–
peroxidase detection system (Vector Laboratories, Burlingame,
CA, USA). The sections were counterstained with 5% cresyl
violet to stain Nissl substance and coverslipped with DPX. The
images were captured at 40× using an Olympus BH4 micro-
scope with a high-resolution camera. The omission of the
primary antibody was used to confirm the specificity of ligand
binding.
a-syn tg mice
Mice overexpressing human WT a-syn under the mThy1 pro-
moter (mThy1-a-syn, Line 61) were used (49,54) (6 m/o, n ¼ 5
mice per group). This model was selected because the mice
develop behavioral motor deficits (40), axonal pathology and ac-
cumulation of C-terminus cleaved a-syn and aggregates in cor-
tical and subcortical regions (72) mimicking PD/DLB (55,56).
As previously described, brains were homogenized and divided
into cytosolic and membrane fractions (56,57). For WB analysis,
20 mg of total protein per lane were loaded into 4–12% Bis–Tris
SDS–PAGE gels and blotted onto membranes. Blotted samples
from non-tg and a-syn tg mice were probed with the following
antibodies: rabbit polyclonal anti-c-Abl (K-12), rabbit polyclonal
anti-pY39 a-syn, rabbit anti-pY125 a-syn, FL a-syn rabbit
polyclonal (Millipore). Incubation with primary antibodies was
followed by species-appropriate incubation with secondary anti-
bodies tagged with horseradish peroxidase (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), visualization with enhanced
chemiluminescence and analysis with a Versadoc XL imaging ap-
paratus (Bio-Rad). Analysis of b-actin (Sigma-Aldrich, USA)
levels was used as a loading control.
ICC analysis was performed in serially sectioned, free-
floating, blind-coded vibratome sections. The sections were
incubated overnight at 48C (54) with the following antibodies:
rabbit polyclonal anti-c-Abl (K-12), rabbit polyclonal
anti-pY39-a-syn, rabbit anti-pY125-a-syn, FL a-syn rabbit
polyclonal (Millipore) followed by tagged secondary antibody,
avidin biotin HRP and diaminobenzidine reactivity. All sections
were processed simultaneously under the same conditions and
experiments were performed in triplicate in order to assess the
reproducibility of results.
Primary cultures of cortical neurons
Primary cortical neurons were prepared from P0 pups from non-tg
mice (C57BL/6JRccHsd, Harlan) or mice lacking a-syn expres-
sion (C57BL/6JOlaHsd, Harlan) as previously described (73).
Briefly, the cerebral cortices and hippocampi were isolatedstereo-
scopically and dissociated by trituration in medium containing
papain (20 U/ml, Sigma-Aldrich). Cortical and hippocampal
neurons were cultured in Neurobasal medium containing B27
supplement, L-glutamine and penicillin/streptomycin (Life Tech-
nologies). The neurons were seeded on coverslips (CS) previously
coated with poly-L-lysine 0.1% (w/v) in water (Sigma-Aldrich) at
a density of 150 000 cells/ml (for ICC analysis) or directly plated
in 6-well plate for biochemistry analysis at a density of
300 000 cells/ml. After 7 days, the cells were treated withcytosine
b-D-arabinofuranoside (Sigma-Aldrich) toa finalconcentrationof
2.3 mM to inhibitglial celldivision.The neurons wereusedafter14
days in culture (2 weeks old).
Lentiviral production and infection of neuronal primary
culture
The production and titration of WT, KD, PP c-Abl, WT a-syn
and GFP lentiviruses were performed as previously described
by Barde et al. (74). The final titers for WT a-syn, WT c-Abl
and KD c-Abl were 1 × 108 transducing units (TU)/ml and
1 × 109 transducing units (TU)/ml for PP c-Abl and GFP lenti-
viruses. Cortical primary neurons (2 weeks old) were infected
for 5 days with WT c-Abl and KD c-Abl. At Day 5, the
neurons were seeded onto CSs and fixed in 4% paraformalde-
hyde (PFA; Sigma-Aldrich) for 20 min at 48C and further ana-
lyzed by ICC. The neurons plated for biochemistry analysis
were treated for 30 min with 100 mM sodium orthovanadate
and 4 mM H2O2 (Sigma-Aldrich) for 30 min at 378C to inhibit
protein tyrosine phosphatases. The neurons were subsequently
lysed in 2× Laemmli buffer and boiled before loading onto a
8% (for c-Abl) or on 15% (for a-syn) SDS–PAGE gels for sub-
sequent detection by WB.
Cell culture and plasmid transfection
HEK293T and HeLa cells were maintained in glutamax-DMEM
(Life Technologies) containing 10% FCS (Gibco, Life Technolo-
gies), 100 mg/ml of streptomycin and 100 U/ml of penicillin (Life
Technologies). Neuroblastoma M17 cells and SH-SY5Y stable
cell lines for a-syn were maintained in 50% F-12 and 50%
MEM media supplemented in 10% FCS, 100 mg/ml streptomycin
and 100 U/ml penicillin (Life Technologies). The SH-S5Y5
stable cell line culture medium was supplemented with 1%
G418 (Life Technologies). The 293T cells were transfected
using a standard calcium phosphate transfection protocol (75).
HeLa and M17 cells were transfected with Effectene (Qiagen,
Switzerland) according to the manufacturer’s instructions.
c-Abl downregulation with siRNA in HEK293T cells
The following siRNA were purchased from Thermofisher
(USA): c-Abl ON-TARGET plus SMARTpool (L-003100-00)
and ON-TARGETplus Non-targeting Pool (D-001810-10)
(scramble). The 293T cells were co-transfected with scramble
(Sc) or siRNA against c-Abl with or without plasmids encoding
for WT c-Abl and a-syn WT using Jet Prime (Polyplus, France)
according to the manufacturer’s instructions. At 48 h post-trans-
fection, the cells were lysed and analyzed by WB.
Semiquantitative RT–PCR
Cortical primaryneuronswere treated for 16 h withnilotinib, ima-
tinib, GNF-2 or DMSO (as a negative control). Cells were then
lysed and mRNAs were extracted using RNeasy kit (Qiagen,
Switzerland) following the manufacturer’s instructions. The
Human Molecular Genetics, 2014, Vol. 23, No. 11 2875
semiquantitative RT–PCR was run using Transcriptor One Step
kit (Roche Diagnostic, Switzerland) using the following primers:
GAPDH: FWD 5′-CAGGTTGTCTCCTGCGACTT-3′;
REV 5′-GGCCTCTCTTGCTCAGTGTC-3′
c-Abl: FWD 5′-ACAAAGTGGGCCTCAGCAAG-3′;
REV 5′-CATCTGCTCTGAGTTCCGGG-3
a-syn: FWD 5′-GTGGCTGCTGCTGAGAAAAC-3′;
REV 5′-GAGCAGCCGGCAGATCTTAG-3
The PCR products were loaded onto an agarose gel (1%) stained
with SYBR Safe (Life Technologies, Switzerland) and 1 kb plus
DNA ladder was used to estimate the size of the band (Fermen-
tas, Switzerland). Images of the agarose gels were acquired with
Geni Imager (Syngene, Biolabo, Switzerland).
Immunocytochemistry
HeLa or M17 cells were seeded onto CSs (VWR, Switzerland)
and transfected with Effectene (Qiagen) by WT a-syn, Y39F
a-syn, Y125F a-syn or Y39F Y125F a-syn together with WT
c-Abl or KD c-Abl or PP c-Abl. HEK293T cells were seeded
onto CS previously coated with poly-L-lysine (Life Technolo-
gies) and transfected using a standard calcium phosphate proto-
col. Cortical neurons were seeded onto CS previously coated
with poly-L-lysine. Mammalian cell lines were grown for 24 h
and then fixed in 4% PFA (paraformaldehyde) for 20 min at
48C. Neurons were fixed in 4% PFA for 10 min at RT. After
blocking with 3% BSA (bovine serum albumin) in 0.1% Triton
X-100 PBS (phosphate buffer saline) (PBST) for 30 min at
room temperature, mammalian cells or cortical primary
neurons were incubated with primary antibodies (mouse
anti-c-Abl, goat anti-a/g/b-syn, rabbit anti-pY39-a-syn or
rabbit anti-pY125-a-syn) for 1 h at room temperature. The
cells were rinsed five times in PBST and subsequently incubated
with the secondary antigoat Alexa488, antimouse Alexa647 or
antirabbit Alexa568 at a dilution of 1/800 in PBST. The cells
were washed five times in PBST and incubated 30 min at room
temperature in DAPI at 2 mg/ml (Life technologies), before
mounting in polyvinyl alcohol mounting medium with
DABCO (Sigma-Aldrich). The cells were then examined with
confocal laser-scanning microscope (LSM 700, Zeiss) with a
20× or a 63× objective and analyzed using Zen software.
Immunohistochemistry of pY39 in tg mice
To investigate the distribution of the phosphorylated a-syn at
Y39 in vivo, brains from PDGF a-syn tg mice (49), displaying
abundant a-syn accumulation in the neocortex and limbic
system were analyzed. Control experiments were performed
using age-matcheda-syn KO mice (76). Consistent with Nation-
al Institutes of Health (NIH) guidelines for the human treatment
of animals, the mice were sacrificed (at 6 months of age) by deep
anesthesia with chloral hydrate, and the brains were removed and
divided sagittally. Hemibrains were then post-fixed in
phosphate-buffered 4% PFA (pH 7.4) at 48C for 48 h and sec-
tioned at 40 mm using a vibratome 2000 (Leica). The serially
sectioned, free-floating, blind-coded vibratome sections were
incubated overnight at 48C with the homemade rabbit polyclonal
anti-pY39 a-syn specific antibody (1:250), as previously
described (54). The primary antibody incubation was followed
by incubation with goat antirabbit IgG (1:100, Vector) followed
by avidin D-HRP and DAB revelation. The sections were ana-
lyzed with an Olympus bright field microscope.
Cell lysis andWB
Twenty-four hours or 48 h after transfection, the mammalian cell
lines and cortical neurons were treated with pervanadate (100 mM
sodium orthovanadate and 4 mM H2O2) for 20 min at 378C to
inhibit protein tyrosine phosphatases. The mammalian cell lines
were then harvested and lysed in 50 mM Tris, pH 7.5; 150 mM
NaCl; 1% NP-40; 5 mM EGTA and 5 mM EDTA freshly supple-
mented with 50 mM NaF, 1 mM sodium orthovanadate; 1 mM
PMSF; 10 mg TPCK and 1:200 protease inhibitor mixture
(Sigma-Aldrich). The cell lysates were cleared by centrifugation
at 48C for 15 min at 20 000g. The total amount of protein in the
supernatant was estimated using the BCATM protein assay kit
from Thermo Scientific (Switzerland), according to the manufac-
turer’s instructions. Proteins were diluted in Laemmli buffer 5×
(2% SDS, 20% glycerol, 0.05% bromophenol blue, 0.125 M
Tris–HCl, pH 6.8, and 5% b-mercaptoethanol). Cortical neurons
were directly lysed in 2× Laemmli buffer. The cell lysates were
then separated on 8% (c-Abl) or on 15% (pY39, pY125, pS129
and a-syn) SDS–PAGE gels and transferred onto nitrocellulose
membrane (Fisher Scientific, Switzerland). The membranes were
blocked in Odyssey blocking buffer (Li-Cor Biosciences GmbH,
Germany) diluted 1:3 in PBS for 30 min and then incubated with
the appropriate antibodies [rabbit polyclonal anti-c-Abl (K-12),
rabbit polyclonal anti-pY39-a-syn, mouse anti-pY125-a-syn
(BD Transduction Laboratories), mouse monoclonal anti-a-syn
and mouse monoclonal anti-b-actin]. The membranes were
washed three times in PBS 0.1% Tween and then incubated for
1 h with secondary antibodies (goat anti-(anti-mouse) mouse
Alexa647, goat antirabbit Alexa647 from Life technologies or goat
anti-(anti-mouse) mouse Alexa800 from Li-Cor). After three
washes with PBS 0.1% Tween, the specific signals were revealed
using the Li-Cor scanner at a wavelength of 700 or 800 nm.
Immunoprecipitation, in-gel digestion and MS analyses
Two-week-old cultures of primary cortical neurons grown on
10 cm dishes were lysed in 50 mM Tris, pH 7.5; 150 mM NaCl;
1% NP-40; 5 mM EGTA and 5 mM EDTA freshly supplemented
with 50 mM NaF, 1 mM sodium orthovanadate; 1 mM PMSF;
10 mg TPCK and 1:200 protease inhibitor mixture. The cell
lysates were cleared by centrifugation at 48C for 15 min at
20 000g followed by two 30 min incubations with protein
G-magnetic beads (Millipore, Switzerland). Cleared cell
lysates (4 mg) were then incubated overnight at 48C on a
rocking platform without (control) or with 30 mg of anti-a-syn
monoclonal (BD Biosciences). The immune complexes were
precipitated using 50 ml of protein G-magnetic beads for 1 h at
48C on a rocking platform and the beads were washed three
times with the lysis buffer. The immunoprecipitated proteins
were resuspended in 2× Laemmli buffer and boiled before
loading onto a 8% (for c-Abl) or 15% (for a-syn) SDS–PAGE
gels for subsequent detection by WB.
Forty-eight hours after transfection, HEK293T 293T cells
were treated with pervanadate and then lysed as described
above. The cell lysates were cleared by centrifugation at 48C
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for 15 min at 20 000g followed by two 30 min incubations with
protein G-magnetic beads (Millipore, Switzerland). The cell
lysates (1 mg) were incubated overnight at 48C on a rocking plat-
form without (control) or with 10 mg of anti-a-syn monoclonal
(BD Biosciences) or 4 ml of anti-c-Abl monoclonal. The
immune complexes were precipitated with 50 ml protein
G-magnetic beads for 1 h at 48C on a rocking platform and the
beads were washed three times with the lysis buffer. The immu-
noprecipitated proteins were resuspended in 2× Laemmli buffer
and boiled before loading onto 8% (for c-Abl) or 15% (fora-syn)
SDS–PAGE gels for subsequent detection by WB or for in gel
digestion and MS.
For the in-geldigestion, thebandscorresponding toa-syn were
excised after Coomassie Blue staining using Simply Blue Safe
Stain (Life Technologies). Excised bands were destained with
50% ethanol in 100 mM ammonium bicarbonate (AB), pH 8.4,
followed by drying in an evacuated centrifuge, and the proteins
were digested in-gel by covering gel pieces with trypsin solution
made of 12.5 ng/ml in 50 mM AB (pH 8.4), 10 mM calcium chlor-
ideat 378C overnight.The digested peptides were concentrated to
dryness, resuspended in acetonitrile and driedagain.After repeat-
ing this step once more, the dried peptides were resuspended in
20 ml of 20% formic acid, and 2% acetonitrile, desalted on C18
OMIX tips (Agilent Technologies), and analyzed by MALDI–
TOF–TOF tandem MS operating in reflector-positive mode on
a 4800 series MALDI instrument (AB Sciex) and or on a capillary
LC–ESI–MS system (Thermo Scientific LTQ Orbitrap instru-
ment). The collected MS/MS spectra were matched against a
human protein database (SwissProt/TrEMBL) and scored using
Mascot and Sequest algorithms. The data were then analyzed
and presented using Scaffold version 3.0 (Proteome Software).
Plasmid and production of recombinant AAV2/6 viral
vectors
The human-syn cDNA and MaxFP-green (FPmax) were cloned
into the AAV-CMV-MCS backbone (Stratagene). The produc-
tion and titration of the recombinant pseudotyped AAV2/6
vectors (serotype 2 genome/serotype 6 capsid) were performed
as previously described (72). The final titers were 3.88 × 1010
transducing units (TU)/ml (WT a-syn) and 5.1010 TU/ml
(FPmax).
Stereotaxic injections
All surgical and behavioral procedures were performed in ac-
cordance with the Swiss legislation and the European Commu-
nity council directive (86/609/EEC) for the care and use of
laboratory animals. The injections were performed under xyla-
zine/ketamine anesthesia as described by Paleologou et al.
(77). Briefly, male Wistar rats (Charles River Laboratories)
weighing 180–200 g at the time of surgery were placed in the
stereotaxic frame (David Kopf Instruments) and administered
a unilateral intranigral injection of 2 ml of viral suspension,
which corresponds to a viral load of 1.5 × 107 TU.
Tissue processing and IHC
The animals were deeply anesthetized and transcardially per-
fused with 4% paraformaldehyde (PFA; Fluka, Sigma-Aldrich)
at 13 weeks after injection. The brains were removed, post-fixed
for 2 h in 4% PFA, and then placed in 25% sucrose. Coronal sec-
tions (25 mm thick) were cut using a microtome (SM2400;
Leica) and the slices were stored at 2208C in cryoprotection
medium.
ICC analysis was performed as previously described by Paleo-
logou et al. (77). The slices were incubated with anti-c-Abl
primary antibodies [(K12) and (24-11) from Santa Cruz or
from Sigma] and subsequently incubated with biotinylated sec-
ondary antibody (1:200; Vector Laboratories) for DAB
(3,3-diaminobenzidine) (Pierce) revelation. Imaging was per-
formed on a Leica DMI 4000 microscope (Leica LAS software)
equipped with an Olympus AX70 camera.
Relative quantification of WB and statistical analysis
The level of pY39-a-syn or pY125-a-syn was estimated by
measuring the WB band intensity using Image J software (Na-
tional Institute of Health, Bethesda, MD, USA) and normalized
to a-syn and the relative pY39-a-syn and pY125-a-syn protein
levels were presented as [pY39]/[a-syn/actin] or [pY125]/
[a-syn/actin]. The experiments were repeated three times with
the same results. The statistical analysis was performed using
Student’s t-test or ANOVA test followed by Tukey–Kramer
post hoc test. The data were regarded as statistically significant
at P , 0.05 based on the t-test or Tukey–Kramer post hoc test.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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